Yim Chan, MD
Psychiatry · San Francisco, CANPI 1659458289
Payments from drug & device makers
Across 369 payments — averaging $48.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $5K from 14 others
What the payments were for
- Consulting fees$2,30013%
- Food & beverage$15,05585%
- Education$4122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $2,663 |
| Neurocrine Biosciences, Inc. | 49 | $2,354 |
| Teva Pharmaceuticals USA, Inc. | 34 | $2,286 |
| AbbVie(2 entities) | 66 | $2,210 |
| Otsuka America Pharmaceutical, Inc. | 48 | $2,010 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $1,317 |
| Alkermes, Inc. | 25 | $1,046 |
| Lundbeck LLC | 25 | $699 |
| Vanda Pharmaceuticals Inc. | 23 | $667 |
| Axsome Therapeutics, Inc. | 5 | $579 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $464 |
| Sage Therapeutics, LLC | 1 | $350 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $333 |
| Indivior Inc. | 5 | $191 |
| E.r. Squibb & Sons, L.L.C. | 4 | $177 |
| Avanir Pharmaceuticals, Inc. | 1 | $115 |
| Gilead | 1 | $110 |
| Neuronetics, Inc. | 1 | $88 |
| Pfizer | 4 | $68 |
| Novo Nordisk | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$2,078
- ARISTADA$2,000
- INGREZZA$1,209
- VRAYLAR$863
- REXULTI$713
- Auvelity$557
- AUSTEDO$548
- ARISTADA INITIO$500
- LYBALVI$483
- CAPLYTA$478
- Austedo XR$260
- INVEGA TRINZA$251
- UZEDY$244
- ABILIFY MAINTENA$235
- NURTEC ODT$125
- INVEGA SUSTENNA$123
- COBENFY$121
- ABILIFY ASIMTUFII$120
- SUBLOCADE$119
- NUEDEXTA$115
How this compares
$17,767 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 19 | $2,186 |
| Mirtazapine | 58 | $982 |
| Ziprasidone Hcl | 13 | $793 |
| Bupropion XlBupropion Hcl | 11 | $603 |
| Trazodone Hcl | 88 | $549 |
| Risperidone | 103 | $501 |
| Olanzapine | 23 | $444 |
| Duloxetine Hcl | 18 | $392 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $341 |
| Clonazepam | 27 | $269 |
| Citalopram HbrCitalopram Hydrobromide | 25 | $236 |
| RivastigmineRivastigmine Tartrate | 13 | $212 |
| Paroxetine Hcl | 21 | $201 |
| Quetiapine Fumarate | 29 | $196 |
| Escitalopram Oxalate | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Francisco
- John KooSan Francisco$3M
- Corinna GamezSan Francisco$2M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.